Rxivist logo

Flipping the odds of drug development success through human genomics

By Aroon D. Hingorani, Valerie Kuan, Chris Finan, Felix A. Kruger, Anna Gaulton, Sandesh Chopade, Reecha Sofat, Raymond J. MacAllister, John P. Overington, Harry Hemingway, Spiros Denaxas, David Prieto, Juan Pablo Casas

Posted 30 Jul 2017
bioRxiv DOI: 10.1101/170142

Drug development depends on accurately identifying molecular targets that both play a causal role in a disease and are amenable to pharmacological action by small molecule drugs or bio-therapeutics, such as monoclonal antibodies. Errors in drug target specification contribute to the extremely high rates of drug development failure. Integrating knowledge of genes that encode druggable targets with those that influence susceptibility to common disease has the potential to radically improve the probability of drug development success.

Download data

  • Downloaded 1,623 times
  • Download rankings, all-time:
    • Site-wide: 9,582
    • In genomics: 1,066
  • Year to date:
    • Site-wide: 70,861
  • Since beginning of last month:
    • Site-wide: None

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News